Table 1 Clinical characteristics of patients treated with nivolumab.

From: Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer

Variables

Patients (n = 62) n (%)

Age, years

Median (range)

63 (39–87)

Sex

Men

40 (64.5)

Women

22 (35.5)

ECOG performance status

0

9 (14.5)

1

43 (69.4)

2

10 (16.1)

Smoking

Never/light smoker

23 (37.1)

Smoker

39 (62.9)

Histology

Adenocarcinoma

47 (75.8)

Squamous cell carcinoma

15 (24.2)

Mutation type

EGFR mutation

7 (11.3)

ALK or ROS1 rearrangement

1 (1.6)

Wild type

54 (87.1)

Previous treatment

Chemotherapy

35 (56.4)

Targeted therapy

9 (14.5)

Immunotherapy

0 (0)

Surgery

4 (6.4)

Radiotherapy

7 (11.2)

No. of prior therapies

1

29 (46.8)

2

12 (19.4)

>2

21 (33.8)

Back to article page